Liposome News and Research RSS Feed - Liposome News and Research

A liposome is a very tiny, fat-like particle that is made in the laboratory. In medicine, liposomes containing drugs or other substances are used in the treatment of cancer and other diseases. Drugs given in liposomes may have fewer side effects and work better than the same drugs given alone.
Griffith University to collaborate with Olymvax for new vaccine technology that could benefit millions

Griffith University to collaborate with Olymvax for new vaccine technology that could benefit millions

Griffith University will partner with a Chinese pharmaceutical, Olymvax Biopharmaceuticals Inc. for a new vaccine that could benefit millions. [More]
Liposome nanoencapsulation can increase efficacy of bacteriophages in oral phage therapy

Liposome nanoencapsulation can increase efficacy of bacteriophages in oral phage therapy

Scientists at the Universitat Autònoma de Barcelona and the Catalan Institute for Nanoscience and Nanotechnology have developed a nanoencapsulation system with a liposome coating in order to increase the efficacy of bacteriophages in oral phage therapy. [More]
Cornell researchers develop nanoparticle-based drug delivery mechanism for combination cancer therapy

Cornell researchers develop nanoparticle-based drug delivery mechanism for combination cancer therapy

A team of researchers from Cornell University in Ithaca, New York demonstrated a drug delivery mechanism that utilizes two independent vehicles, allowing for delivery of chemically and physically dis-tinct agents. [More]
Extracellular vesicle isolation and characterization: an interview with Dr Carley Ross

Extracellular vesicle isolation and characterization: an interview with Dr Carley Ross

Extracellular vesicles are membrane surrounded structures released by cells in an evolutionally conserved manner. There are three main types of EVs, Exosomes (50-100 nm), Microparticles (200 nm-1 um) and Apoptotic bodies. [More]
UGA investigators find viable treatment for prostate cancer

UGA investigators find viable treatment for prostate cancer

Researchers at the University of Georgia have created a new therapeutic for prostate cancer that has shown great efficacy in mouse models of the disease. They published their findings recently in the journal Nanomedicine: Nanotechnology, Biology and Medicine. [More]
Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

microRNAs (miRs) are small endogenous noncoding RNA molecules (20–23 nucleotides) derived from imperfectly paired hairpin RNA structures naturally encoded in the genome that act specifically as triggering molecules to control translational repression or mRNA degradation. [More]
WRAIR researchers publish results from Plasmodium vivax malaria vaccine study

WRAIR researchers publish results from Plasmodium vivax malaria vaccine study

Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model. [More]
Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator Pharmaceuticals, Inc. today announced that the Phase 3 clinical trial of VYXEOS (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML) has reached its pre-specified number of events required for the analysis of overall survival. [More]
CASI Pharmaceuticals receives $10.3 million in strategic financing

CASI Pharmaceuticals receives $10.3 million in strategic financing

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces it has received approximately $10.3 million in a strategic financing previously announced on September 21, 2015. [More]
New nanotechnology approach could transform gliomas from death sentence into treatable condition

New nanotechnology approach could transform gliomas from death sentence into treatable condition

An MRI contrast agent that can pass through the blood-brain barrier will allow doctors to detect deadly brain tumors called gliomas earlier, say Penn State College of Medicine researchers. This ability opens the door to make this fatal cancer treatable. [More]
Marqibo now available to leukemia patients through myTomorrows' Internet-based platform

Marqibo now available to leukemia patients through myTomorrows' Internet-based platform

myTomorrows (Amsterdam, the Netherlands), announced today that it has started a collaboration with Spectrum Pharmaceuticals, Inc. (Henderson, USA) to provide access to its liposome-encapsulated vincristine for treatment of Philadelphia chromosome negative acute lymphoblastic leukemia. [More]
New study compares outcomes from two postoperative pain control methods in knee replacement patients

New study compares outcomes from two postoperative pain control methods in knee replacement patients

A new study published today in The Journal of the American Osteopathic Association compared outcomes from two types of postoperative pain control methods in a group of patients who had both of their knees replaced. [More]
Crucial tumor-suppressing gene protects immune attack against lung cancer

Crucial tumor-suppressing gene protects immune attack against lung cancer

A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute. [More]
New nanocarriers may effectively deliver therapeutic drug to GBM tumors

New nanocarriers may effectively deliver therapeutic drug to GBM tumors

Glioblastoma multiforme, a cancer of the brain also known as "octopus tumors" because of the manner in which the cancer cells extend their tendrils into surrounding tissue, is virtually inoperable, resistant to therapies, and always fatal, usually within 15 months of onset. [More]
CASI reports net loss of $1.6 million for third quarter 2015

CASI reports net loss of $1.6 million for third quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and nine months ended September 30, 2015. [More]
Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis. The group began at Northwestern University, Chicago, under the direction of Dr. David McPherson and he continues to lead the group. [More]
Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma

Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma

Today, The U.S. Food and Drug Administration approved a novel therapy for patients with metastatic pancreatic adenocarcinoma – the most common form of pancreatic cancer – whose disease has progressed following gemcitabine-based therapy, offering new hope against a disease that will claim the lives of more than 40,000 individuals this year. [More]
New combination treatment approved by FDA for metastatic pancreatic cancer

New combination treatment approved by FDA for metastatic pancreatic cancer

The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. [More]
CWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatment

CWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatment

A Case Western Reserve University researcher has received a 5-year, $2.82 million National Institutes of Health grant to make, in essence, stealth bombs that slip past the brain's defenses to attack an incurable form of cancer. [More]
Researchers come up with new design for a better liposome

Researchers come up with new design for a better liposome

Using computational modeling, researchers at Carnegie Mellon University, the Colorado School of Mines and the University of California, Davis have come up with a design for a better liposome. Their findings, while theoretical, could provide the basis for efficiently constructing new vehicles for nanodrug delivery. [More]
Advertisement
Advertisement